Connection

Contact Us
If you have any questions or feedback please contact us.

Search Results to David Ross Camidge

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Camidge, David

One or more keywords matched the following items that are connected to Camidge, David

Item Type	Name
Academic Article	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Academic Article	Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
Academic Article	Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
Academic Article	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Academic Article	Characteristics of lung cancers harboring NRAS mutations.
Academic Article	Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
Academic Article	Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
Academic Article	Preclinical and clinical estimates of the basal apoptotic rate of a cancer predict the amount of apoptosis induced by subsequent proapoptotic stimuli.
Academic Article	A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.
Academic Article	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.
Academic Article	Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Academic Article	Targeting ALK, ROS1, and BRAF kinases.
Academic Article	Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
Academic Article	Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Concept	Proto-Oncogenes
Concept	Proto-Oncogene Proteins B-raf
Concept	Proto-Oncogene Proteins c-bcl-2
Concept	Proto-Oncogene Proteins p21(ras)
Concept	Proto-Oncogene Proteins c-ret
Concept	Proto-Oncogene Proteins c-met
Concept	Proto-Oncogene Proteins
Concept	Proto-Oncogene Proteins c-kit
Concept	Proto-Oncogene Proteins c-akt
Academic Article	Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
Academic Article	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Academic Article	Realizing the potential of plasma genotyping in an age of genotype-directed therapies.
Academic Article	Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Academic Article	Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Academic Article	Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure.
Academic Article	Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
Academic Article	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Academic Article	An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
Academic Article	Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
Academic Article	Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Academic Article	Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
Academic Article	Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
Academic Article	The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Academic Article	Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.
Academic Article	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Academic Article	First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance.
Academic Article	ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events.
Academic Article	Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Academic Article	DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung?Cancer.
Academic Article	Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
Academic Article	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
Academic Article	Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Academic Article	Untapped potential: recognising CNS opportunities in early oncology drug development.
Academic Article	Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
Academic Article	Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
Academic Article	Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Academic Article	GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients.
Academic Article	Crizotinib in Patients With MET-Amplified NSCLC.
Academic Article	Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib.
Academic Article	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
Academic Article	Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data.
Academic Article	Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Academic Article	Oncogene Overlap Analysis of Circulating Cell-free Tumor DNA to Explore the Appropriate Criteria for Defining MET Copy Number-Driven Lung Cancer.
Academic Article	NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
Academic Article	The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX).
Academic Article	A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Academic Article	Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.

Search Criteria

Proto Oncogenes